GlobeNewswire

SERSTECH AB: Half-year report 1 January – 30 June 2020

Share

Serstech Group -                                                                    Serstech Group –   
Second quarter 2020                                                              Period 1 January – 30 June 2020

Net sales: KSEK 308 (5 089)                                                   Net sales: KSEK 6321 (8 340)
Profit for the period: KSEK -6 820 (-3 349)                              Profit for the period: KSEK -10 025 (-7 008)
Earnings per share SEK -0,10 (-0,05)                                      Earnings per share SEK -0,14 (-0,11)
Earnings per average number of shares: SEK -0,10 (-0,05)    Earnings per average number of shares: SEK -0,14 (-0,11)  

The second quarter was naturally heavily influenced by the ongoing pandemic and our sales was significantly lower than normal. In April and the first half of May, the vast majority of ongoing tenders were either postponed indefinitely or cancelled. In late May and in June, several of the postponed or cancelled tenders were reopened, some end-customers mentioning the reason being an increased narcotics problem in the country. In June, we also noted a significantly higher  activity level among our partners, with customer meetings and demonstrations being possible again in some regions.

The plan and goal for 2020 was to grow our revenue well beyond 100% and we also had high ambitions in our product development roadmap for the year. The plan was to grow our R&D capacity in both Sweden and Romania and double our sales team. As a direct result of the effects from Covid-19, we initiated a cost-cutting program in mid-March. We have asked eleven colleagues to leave the company and managed to achieve an overall fixed cost reduction by more than 60% per month from April to October. The majority of staff reductions has been done in Lund, leaving the team in Cluj Napoca relatively untouched.

The combination of significantly reduced cost and the reopening of some tenders makes us cautiously optimistic that the market will start to normalize in the third or fourth quarter. We expect to be able to maintain a very low cost level until at least the end of the year, partially due to the ongoing reduction in working hours for the Swedish team. Since we do not use our own resources or cash for sourcing and production, our fixed costs will not automatically increase when the volumes start to go up again. We therefore expect to see improvements in our cash flow the coming quarters.  

In April, we announced the new instruments Serstech Arx and Arx+, which are intended for the security and pharmaceutical industry, respectively. The differences between the two instruments are that the Arx+ contains a barcode reader and complies with FDA’s regulations governing the pharmaceutical production industry. Both instruments have our patented autofocus solution, built-in Wi-Fi, next generation analysis algorithms and a completely redesigned hardware and user interface. The new products have created a lot of buzz in the market and positive response from partners and endcustomers. We expect the products to generate initial sales already in Q4 this year, even though the volumes are hard to predict, due to the current market situation.

For most of this year, we have reduced capacity in R&D due to the reduction of the team size and reduced working hours for the remaining team. Nevertheless, we plan to launch ChemDash 2.0 in September and reshape and significantly improve our software offering. The new ChemDash platform, rewritten from scratch, will be introduced in three dif ferent versions – ChemDash Lite, ChemDash Pro and ChemDash Pro+. ChemDash Lite is free and is included with any Serstech instrument and has limited functionality. ChemDash Pro is our first premium software and will be sold with subscription and perpetual license options. ChemDash Pro+ is like Pro but complies with the FDA regulations for the pharmaceutical market. The new ChemDash platform introduces a licensing mechanism, which in the future will allow us to sell subscriptions to updates of our substance libraries. At the moment, the security market does not accept the subscription business model, but we expect that to gradually change over the coming years.

The overall feeling after the end of Q2 is positive and we think that the second half of the year will be better than what we initially feared and prepared for. The cost reductions we have done, in combination with the variety of new products, put us in a good competitive position to quickly resume sales, without adding any fixed cost.

For further information, please contact:

Stefan Sandor,
CEO, Serstech AB
Phone: +46 739 606067
Email: ss@serstech.com

Thomas Pileby,
Chairman of the Board, Serstech AB
Phone: +46 702 072643
Email: tp@serstech.com

Company website: www.serstech.com

This is information that Serstech AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 08:45 CET on July 20, 2020.

Certified advisor to Serstech is Västra Hamnen Corporate Finance AB, phone: 040-20 02 50, e-mail: ca@vhcorp.se

About Serstech
Serstech delivers solutions for chemical identification and has customers across the world, mainly in the safety and security industry. Typical customers are customs, police authorities, security organizations and first responders. The solutions and technology are however not limited to security applications and potentially any industry using chemicals of some kind could be addressed by Serstech’s solution. 

Serstech is traded at Nasdaq First North Growth Market and more information about the company can be found at www.serstech.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Saniona announces outcome of warrant exercise23.9.2020 19:00:00 CESTPress release

PRESS RELEASE September 23, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, announced today the outcome in the exercise of warrants of series TO 2, that was issued in connection with Saniona’s rights issue and directed issue in the first quarter of 2020. During the period September 7 – 21, 2020, holders of warrants of series TO 2 had the right to subscribe for new shares, by exercise of warrants. In total, 1,329,141 warrants of series TO 2 were exercised, corresponding to a subscription rate of approx. 90 percent. Saniona will thereby receive proceeds of approx. SEK 33.2 million (USD 3.6 million), before issue costs, which amount to approx. SEK 0.4 million. Number of shares and share capital Saniona will receive proceeds of approx. SEK 33.2 million, before issue costs. Issue costs amount to approx. SEK 0.4 million. When the new shares have been registered with the Swedish Companies Registration Office (“Bolagsverket”), the total number o

Saniona meddelar utfall i optionsinlösen23.9.2020 19:00:00 CESTPressemelding

PRESSMEDDELANDE 23 september 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelade idag utfallet i inlösen av teckningsoptioner av serie TO 2, vilka emitterades i samband med Sanionas företrädesemission och riktade emission under det första kvartalet 2020. Under perioden 7 – 21 september 2020 har innehavare av teckningsoptioner av serie TO 2 kunnat teckna aktier med stöd av teckningsoptioner. Totalt nyttjades 1 329 141 teckningsoptioner av serie TO 2, vilket motsvarar en nyttjandegrad om cirka 90 procent. Saniona tillförs därmed cirka 33,2 MSEK (3,6 MUSD) före emissionskostnader, vilka beräknas uppgå till cirka 0,4 MSEK. Antal aktier och aktiekapital Saniona tillförs cirka 33,2 MSEK före emissionskostnader. Emissionskostnaderna beräknas uppgå till cirka 0,4 MSEK. När de nya aktierna har registrerats hos Bolagsverket kommer antalet aktier i Saniona uppgå till 62 372 831 stycken och aktiekapitalet uppgå till 3 118 641,

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING23.9.2020 16:20:00 CESTPress release

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-09-25 Transaction type:SEK CreditTender date:2020-09-25Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-09-29Final repayment date2024-09-30Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON SEPTEMBER 25 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: eol@riksbank.se Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at http://www.riksbank.se

Cypress Development to Collaborate on Lithium Research Projects23.9.2020 14:00:10 CESTPress release

VANCOUVER, British Columbia, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Cypress Development Corp. (TSX-V:CYP) (OTCQB:CYDVF) (Frankfurt:C1Z1) (“Cypress” or “the Company”), developer of a world class lithium claystone deposit in Nevada, announced today, the Company, as an industrial partner with several high tech research entities, has been encouraged along with its partners in full project proposal submissions to the Department of Energy (DOE), Office of Energy Efficiency and Renewable Energy (EERE). This has culminated in the recent formal submittal of two lithium project proposals for research to be conducted over the next three years. The first project is in collaboration with the University of Utah, Colorado School of Mines, and Cornell University, and is titled "Highly Selective Resource Independent Lithium Extraction Processes." This technology will demonstrate the use of Next Generation Lithium Ion Sieve Technology (NGLIST) as an innovative and low-impact processing method for recovering

Nordic American Tankers Ltd (NYSE: NAT) – NAT orders two -2- Suezmax newbuildings in South Korea23.9.2020 11:54:47 CESTPress release

September 23, 2020 Dear Shareholders and Investors, We wish to announce that NAT has entered into two -2- suezmax newbuilding contracts in South Korea, increasing our fleet of suezmaxes to 25 units. The combination of specifications, quality of yard, price, payment terms and deliveries make this an attractive investment for NAT and is consistent with our strategy to expand and renew our fleet. The scheduled deliveries of the ships are in the first half of 2022. Through the years we have enjoyed an excellent relationship with the shipbuilding sector in South Korea, and we are happy to conclude further suezmax newbuilding contracts with Samsung Heavy Industries Ltd. NAT will consider various financing alternatives prior to deliveries. The payment terms of the newbuildings are 10/10/10/10 with 60% of the building price on deliveries. The two first instalments of the vessels have already been funded. The main focus of NAT is always to pay quarterly dividends, which we have done every singl